The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6924-6934

  Sharpe, Kevin ^a   Stewart, Grant D ^f   MacKay, Alan ^c   Van Neste, Christophe ^j   Rofe, Charlotte ^a   Berney, Dan ^a   Kayani, Irfan ^b   Bex, Axel ⁱ   Wan, Elaine ^c   O'Mahony, Fiach C ^f   O'Donnell, Marie ^f   Chowdhury, Simon ^d   Doshi, Rukma ^a   Ho Yen, Colan ^a   Gerlinger, Marco ^a   Baker, Dawn ^g   Smith, Neil ^g   Davies, Barry ^g   Sahdev, Anju ^a   Boleti, Ekaterini ^e   De Meyer, Tim ^j   Van Criekinge, Wim ^j   Beltran, Luis ^a   Lu, Yong Jie ^a   Harrison, David J ^f,h   Reynolds, Andrew R ^c   Powles, Tom ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g ASTRAZENECA   (United Kingdom)

^h UNIVERSITY OF ST ANDREWS   (United Kingdom)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^j GHENT UNIVERSITY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PAZOPANIB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE KINASE INHIBITOR; S6 KINASE; SCATTER FACTOR RECEPTOR; SUNITINIB; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; CARCINOMA, RENAL CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890632231     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1631     Document Type: Article

References (37)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
2. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
4. Sonpavde G, Choueiri TK. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer 2012;107:1009-16.
5. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9: 2793-802.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
7. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012;11:1510-7.
8. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in suni-tinib-resistant tumors. Cancer Res 2010;70:10090-100.
9. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011;30:1183-93.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDer-mott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2012;31:181-6.
12. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961-71.
13. Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer 2011;47:690-6.
14. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
15. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22.
16. Boleti E, Sarwar N, Jones R, Chowdhury S, Crabb S, Shamash J, et al. The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. J Clin Oncol 30, 2012, (Suppl 5; abstr 427).
17. Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 2011;60: 448-54.
18. Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 2011; 78:832-7.
19. Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010;222:282-98.
20. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-89.
21. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG. Whole-genome DNA methylation profiling using Methyl Cap-seq. Methods 2010;52:232-6.
22. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011;17:6021-8.
23. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82.
24. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103: 763-73.
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
26. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15: 220-31.
27. Ellis LM, Reardon DA. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol 2010;11:809-11.
28. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic ade-nocarcinoma. Am J Surg Pathol 1994;18:979-91. (Pubitemid 24301720)
29. Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84:115-22.
30. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibro-blast growth factor/fibroblast growth factor receptor system in angio-genesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
31. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87.
32. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesen-chymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21:66-81.
33. Cao Y, Zhang ZL, Zhou M, Elson P, Rini B, Aydin H, et al. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer 2012;119:313-24.
34. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vascu-lature with kinase inhibitors. J Clin Invest 2003;111:1287-95. (Pubitemid 36554699)
35. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H, et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006;116: 642-51. (Pubitemid 43326873)
36. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion inter-leukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10:275-81.
37. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.